Hans-Peter Albert Ostler

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. The company was founded in 2015 and is headquartered in Moelndal, Sweden.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

RGNT Electric AB is a Swedish company that specializes in electric motorcycles. The company is based in Kungsbacka, Sweden. The company's range of motorbikes is both timeless and forward-thinking. RGNT Electric was founded in 2019 by Jonathan Åström. Göran Karlsson has been the CEO of the company since January 12, 2023.

Ancoria Insurance Ltd. provides insurance services. It offers life insurance policies and occupational pension schemes. The company was founded by Sievert Larsson in 1987 and is headquartered in Nicosia, Cyprus.

Entreprenörskapital i Sverige AB provides activities of securities and commodity brokers. It attracts companies to support companies in a start-up phase. It is the products of the collective wealth of risk capital experience. It desires to explore new approaches to investing in unlisted companies. It delivers benefits to investors, entrepreneurs, customers, and society. The company was founded by Raymond Peter Wendel on January 12, 2011 and is headquartered in Gothenburg, Sweden.

Entreprenörskapital i Sverige AB provides activities of securities and commodity brokers. It attracts companies to support companies in a start-up phase. It is the products of the collective wealth of risk capital experience. It desires to explore new approaches to investing in unlisted companies. It delivers benefits to investors, entrepreneurs, customers, and society. The company was founded by Raymond Peter Wendel on January 12, 2011 and is headquartered in Gothenburg, Sweden.

Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022.

RGNT Electric AB is a Swedish company that specializes in electric motorcycles. The company is based in Kungsbacka, Sweden. The company's range of motorbikes is both timeless and forward-thinking. RGNT Electric was founded in 2019 by Jonathan Åström. Göran Karlsson has been the CEO of the company since January 12, 2023.